Agilent Technologies Inc. is bringing the latest mass spectrometry technology to its collaboration with a New York college in research into a deadly and progressive neurodegenerative disease.

Agilent is collaborating with Dr. Steven Gross, a faculty member in the Department of Pharmacology at Weill Cornell Medical College, to advance research in amyotrophic lateral sclerosis, also known as Lou Gehrig’s disease.

Agilent is providing the latest mass spectrometry technology to support Dr. Gross’ research, working toward an understanding of how the most common form of this disease – sporadic amyotrophic lateral sclerosis (sALS) – develops in the body and affects the nerve cells in the brain and spinal cord.

The Agilent 6230B LC TOF and 6550A LC Q-TOF mass spectrometers will be crucial to investigating the molecular underpinnings of this form of ALS, empowering the team to apply a multi-disciplinary-based approach to understanding the roots of the disease.

The mass spectrometers will be housed in the laboratory of Dr. Gross, an internationally recognised expert in the use of mass spectrometry-based metabolomics.

“We’re very excited to ally ourselves with Agilent to extend our planned attack on the sporadic form of ALS,” Dr. Gross said. “Our newly established scientific collaboration offers a rare opportunity to obtain and integrate multi-omics data, with the potential to yield an unprecedented understanding of the molecular basis for this devastating disease.”

“We anticipate that this scientific work with Agilent will continue into the future as we apply multi-omics approaches to other poorly understood diseases with unmet clinical needs.”